IP Library Granted Patent US 9,375,398
Granted Patent B2
US 9,375,398 · App. 14/202,418 · Granted Jun 28, 2016

Peptides for skin rejuvenation and methods of using the same

Inventor: Frank Dreher (San Francisco, CA)
Assignee: Neocutis S.A.
A61K9/0019A61K8/64A61K9/0014A61K38/05A61K38/06A61K38/07A61Q19/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,375,398
App. No.
14/202,418
Granted
Jun 28, 2016
Kind
B2
Abstract

The invention provides compositions for stimulating the formation of one or more extracellular matrix components that contain a lipoaminoacid derivative of the tripeptide carnosine such as N-Octanoyl Carnosine. Also provided are compositions containing N-Octanoyl Carnosine in combination with selected tripeptide and/or tetrapeptides as well as pharmaceutical and/or cosmetic compositions containing such compositions. The invention further provides methods of using the compositions and compositions of the invention to treat, alleviate, and/or ameliorate a symptom, condition, disorder, or disease of the skin or mucosa, wherein the symptom, condition, disorder, or disease is associated with changes in extracellular matrix components.

Claims (15)

1. A composition for stimulating the formation of one or more extracellular matrix components in skin or mucosa, comprising N-Octanoyl carnosine, the lipoaminoacid derivative of the tripeptide GHK (N-Palmitoyl-GHK), and the tetra-peptide GEKG (SEQ ID NO:1) at a weight ratio of 4:1:5, wherein the composition is formulated for topical or subcutaneous administration.

2. The composition of claim 1 , wherein the composition further comprises one or more carriers or excipients suitable for topical administration or subcutaneous administration.

3. The composition of claim 2 , wherein the composition stimulates the formation of one or more extracellular matrix components selected from the group consisting of collagen I, collagen III, collagen V, collagen VI, collagen VII, collagen XVI, elastin, laminin, hyaluronic acid, fibrillin, heparan sulfate proteoglycan 2, and combinations thereof.

4. The composition of claim 3 , wherein the composition additionally stimulates the formation of one or more extracellular matrix components predominantly associated with skin aging selected from the group consisting of collagen I, collagen VII, elastin, hyaluronic acid, and combinations thereof.

5. The composition of claim 3 , wherein the composition stimulates formation of hyaluronic acid.

6. The composition of claim 2 , wherein the composition is suitable for topical administration in humans on skin, aged skin, damaged skin, skin after cosmetic and dermatological procedures, atrophic skin, atrophic mucosa, wounded skin, vulva, vagina, atrophic vulva, atrophic vagina, vulvovaginal atrophy.

7. The composition of claim 5 , wherein the composition is suitable for topical administration in humans on skin, aged skin, damaged skin, skin after cosmetic and dermatological procedures, atrophic skin, wounded skin, vulva, vagina, atrophic vulva, atrophic vagina.

8. The composition of claim 5 , wherein the combination of N-Octanoyl Carnosine, tripeptide, and tetrapeptide stimulates the production of extracellular matrix components in skin or epithelial cells to a greater degree than any one or two active ingredients alone.

9. The composition of claim 2 , wherein the composition comprises between about 0.0001% to 10% per weight of N-Octanoyl Carnosine.

10. The composition of claim 8 , wherein the composition comprises between about 0.0001% to 10% per weight of N-Octanoyl Carnosine.

11. The composition of claim 2 , wherein the composition comprises about 0.004% per weight of N-Octanoyl Carnosine; about 0.001% per weight of Palmitoyl-GHK, and about 0.005% per weight of GEKG (SEQ ID NO:1), and one or more acceptable carriers or excipients suitable for topical application in humans on skin, aged skin, damaged skin, skin after cosmetic and dermatological procedures, wounded skin, atrophic skin, atrophic mucosa, atrophic vulva, atrophic vagina.

12. A pharmaceutical composition comprising the composition of claim 2 and one or more pharmaceutically acceptable carriers.

13. A cosmetic composition comprising the composition of claim 1 and one or more cosmetically acceptable carriers.

14. A kit comprising, in one or more containers, the pharmaceutical composition of claim 12 and instructions for use.

15. A kit comprising, in one or more containers, the cosmetic composition of claim 13 and instructions for use.

Assignments (3)
CORRECTIVE ASSIGNMENT TO CORRECT THE ADDRESS OF ASSIGNEE PREVIOUSLY RECORDED ON REEL 041940 FRAME 0065. ASSIGNOR(S) HEREBY CONFIRMS THE CONVEYANCE FROM NEOCUTIS SA TO ANTEIS SA. Recorded Apr 28, 2017
From: NEOCUTIS SA
To: ANTEIS SA
Reel/Frame 042359/0065 →
MERGER Recorded Mar 9, 2017
From: NEOCUTIS SA
To: ANTEIS SA
Reel/Frame 041940/0065 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2014
From: DREHER, FRANK
To: NEOCUTIS S.A.
Reel/Frame 032686/0222 →
Continuity (2)
Provisional Application 61779601 · Mar 13, 2013
Related Publication 20140309173A1 · Oct 16, 2014